MannKind Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 414

Market Cap: $1.4B

Website

Clinical Trials

A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus
Healthy Subjects

Interventions: Drug: Technosphere Insulin (TI) Inhalation Powder
Drug: Albuterol (Salbutamol)
Drug: Fluticasone

First Posted Date: 2008-05-07

Last Posted Date: 2012-06-13

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 13

Registration Number: NCT00674050

Locations: 🇬🇧
ICON Development Solutions, Manchester, United Kingdom, United Kingdom

A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics

Phase 1

Completed

Conditions: Asthma
Diabetes Mellitus

Interventions: Drug: Technosphere Insulin Inhalation Powder
Drug: Salbutamol (Albuterol)
Drug: Methacholine chloride

First Posted Date: 2008-05-07

Last Posted Date: 2012-06-13

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 30

Registration Number: NCT00673621

Locations: 🇬🇧
ICON Development Solutions, Manchester, United Kingdom
🇬🇧
Medicines Evaluation Unit (MEU), Manchester, England, United Kingdom

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Phase 2

Completed

Conditions: Diabetes Mellitus: Type 1

Interventions: Drug: RAA Population
Drug: Technosphere® Insulin Inhalation Powder
Drug: Technosphere Insulin® Inhalation Powder

First Posted Date: 2008-04-21

Last Posted Date: 2014-10-16

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 29

Registration Number: NCT00662857

Locations: 🇺🇸
Profil Institute for Clinical Research Inc., Chula Vista, California, United States
🇺🇸
Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: MKC253 Inhalation Powder
Drug: Technosphere Inhalation Powder
Drug: subcutaneous injection

First Posted Date: 2008-03-25

Last Posted Date: 2012-06-14

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 20

Registration Number: NCT00642538

Locations: 🇳🇱
University Medical Centre Groningen, Zuidlaren, Netherlands

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Completed

Conditions: Diabetes Mellitus
Upper Respiratory Infection

Interventions: Drug: Technosphere Insulin

First Posted Date: 2008-03-25

Last Posted Date: 2014-12-03

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 20

Registration Number: NCT00642681

Locations: 🇷🇺
RAAMS Endocrinology and Diabetology Department, Moscow, RUS, Russian Federation
🇷🇺
Clinical Pharm Dept of Yaroslavl Clin Hospital, Yaroslavl, RUS, Russian Federation
🇷🇺
FSI Principal Military Clinical Hospital n.a. academician N.N. Burdenko of the Ministry of Defense, Moscow, Russian Federation

and more 21 locations

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Phase 3

Terminated

Conditions: Type 1 Diabetes Mellitus
Asthma
Type 2 Diabetes Mellitus
Moderate Chronic Obstructive Pulmonary Disease

Interventions: Drug: Technosphere® Insulin
Drug: Usual Care

First Posted Date: 2008-03-25

Last Posted Date: 2017-04-14

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 34

Registration Number: NCT00642616

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Phase 1

Completed

Conditions: Mild Nephropathy
Moderate Nephropathy
Diabetes Mellitus

Interventions: Drug: Technosphere Inhalation Powder

First Posted Date: 2008-02-29

Last Posted Date: 2013-12-17

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 36

Registration Number: NCT00626249

Locations: 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Qualia Clinical Research, Omaha, Nebraska, United States
🇺🇸
Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, United States

A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Technosphere Insulin

First Posted Date: 2007-12-11

Last Posted Date: 2014-10-16

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 30

Registration Number: NCT00570687

Locations: 🇩🇪
Profil Institute for Metabolic Research, Neuss, GER, Germany

Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Type 2

First Posted Date: 2007-10-05

Last Posted Date: 2009-10-14

Lead Sponsor: Mannkind Corporation

Registration Number: NCT00539890

Locations: 🇷🇺
Russian State Medical University City Hospital # 4, Moscow, RUS, Russian Federation
🇷🇺
Ural State Medical Academy of Post-Graduate Education Municipal Clinical Hospital # 3, Chelyabinsk, RUS, Russian Federation
🇷🇺
Moscow Medical Academy, Moscow, RUS, Russian Federation

and more 29 locations

A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

First Posted Date: 2007-10-04

Last Posted Date: 2009-10-14

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 110

Registration Number: NCT00539396

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy